From Antibody Engineering to Clinical Development in EMB-06 – A BCMA/ CD3 Targeting BiTE
Time: 3:15 pm
day: Day 1
Details:
- Exploring antibody engineering for EMB-06
- Delving into the shift from oncology to autoimmune indication – targeting both multiple myeloma and autoimmune diseases
- Looking into phase 1 trial results for EMB-06 and next steps
